Study opens new avenue for immunotherapy drug development
In a new study published today in Nature Biomedical Engineering, researchers at The University of Texas MD Anderson Cancer Center have...
AACR: Trio of studies highlights promising early results...
ABSTRACTS CT037, CT038, CT042
Three early-phase clinical studies presented by researchers from The University of Texas MD Anderson...
AACR: PARP1-selective inhibitor demonstrates early efficacy...
The first-in-class PARP1-selective inhibitor saruparib demonstrated encouraging early efficacy and a favorable safety profile in...